Ki-67 immunolabeling in pre-malignant lesions and carcinoma of the prostate. Histological correlation and prognostic evaluation

European Journal of Histochemistry

Volumn 47, Issue 2, 2003, Pages 123-127

  Muñoz, Elisa ^a   Gomez F ^b   Paz, J I ^a   Casado, I ^b   Silva, J M ^a   Corcuera, M T ^b   Alonso, M J ^b  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Carcinoma; Immunohistochemistry; Ki 67; Pre malignant lesions; Prostate

Indexed keywords

BIOLOGICAL MARKER; KI 67 ANTIGEN;

ANTIBODY LABELING; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PRECANCER; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; TUMOR BIOPSY;

EID: 17744407990     PISSN: 1121760X     EISSN: None     Source Type: Journal    
DOI: 10.4081/816     Document Type: Article

References (25)

1. Aaltomaa S, Lipponen P, Vesalainen S, Ala-Opas M, Eskelinen M, Syrjänen K. Value of Ki-67 immunolabeling as a prognostic factor in prostate cancer. Eur Urol 1997;32:410-5.
2. Bai XZ, Masters JR, O'Donoghue N, Kirby R, Pan LX, Young M, et al. Prognostic markers in clinically localised prostate cancer. Int J Oncol 1999;14:785-91.
3. Bettencourt MC, Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Moul JW. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol 1996;156:1064-8.
4. Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics, 1994. Cancer J Clin 1994;44:7-26.
5. Borre M, Bentzen SM, Nerstom B, Overgaard J.Tumor cell proliferation and survival in patients with prostate cancer followed expectantly. J Urol 1998;159:1609-14.
6. Bostwwick DG, Grignon DJ, Hammond ME, Amin MB, Cohen M, Crawford D, et al. Prognostic factors in prostate cancer. College of American Pathologists consensus statement 1999. Arch Pathol Lab Med 2000;124:995-1000.
7. Brown C, Sauvageot BS, Kahane H, et al. Cell proliferation and apoptosis in prostate cancer: correlation with pathologic stage? Mod Pathol 1996;9:205-9.
8. Budenfort L, Sauter G, Moch H, Schmid HP, Gasser TC, Jordan P, et al. ki-67 labeling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 1996;178:437-41.
9. Cher ML, Stephenson RA, James BC, Carroll PR. Cellular proliferative fraction of metastatic lymph nodes predicts survival in stage D1(TxN+M0) prostate cancer. J Urol 1996;155:1674-7.
10. Cohen RJ, McNeal J E, Baillie T. Patterns of differentiation and proliferation in intraductal carcinoma of the prostate: significance for cancer progression. Prostate 2000;43:11-9.
11. Frankel KA. Intraepithelial melanocytic neoplasia: a classification by pattern analysis of proliferation of atypical melanocytes. Am J Dermatopathol 1987;9:80.
12. Helpap B. Cell Kinetic studies on prostatic intraepithelial neoplasia (PIN) and atypical adenomatous hyperplasia (AAH) of the prostate. Pathol Res Pract 1995;191:904-7.
13. Hepburn PJ, Glynne-Jones E, Goddard L, Gee JM, Harper ME. Cell proliferation in prostatic carcinoma: comparative analysis of Ki-67, MIB-1 and PCNA. Histochem J 1995;27:196-203.
14. Hirai K, Kumakiri M, Ueda K, Imamura Y, Noriki S, Nishi Y, et al. Clonal evolution and progression of 20-methylcholanthrene-induced squamous cell carcinoma of mouse epidermis as revealed by DNA instability and other malignancy markers. Eur J Histochem 2001;45:319-32.
15. Iwasa M, Imamura Y, Noriki S, Nishi Y, Kato H, Fukuda M. Immunohistochemical detection of early-stage carcinogenesis of oral leukoplakia by increased DNA-instability and various malignancy markers. Eur J Histochem 2001;45:333-46.
16. Keshgegian AA, Johnston E, Cnaan A. Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers in prostate carcinoma. Am J Clin Pathol 1998;110:443-9.
17. Lowell WR. Carcinoma in situ. In: Page DL, Anderson TJ, Eds. Diagnostic histopathology of the breast. New York: Churchill-Livingstone; 1987. p. 157.
18. Montironi R, Galluzzi CM, Diamanti L, Giannulis I, Pisani E, Scarpelli M. Prostatic intraepitelial neoplasia: Expression and localization of proliferating cell nuclear antigen (PCNA) in epithelial, endothelial and stromal nuclei. Virchows. Arch 1993;422:185-92.
19. Moul JW, Bettencourt MC, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastasa S, et al. Protein expression of p53, bcl-2, and Ki-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery 1996;120:159-66.
20. Myers RB, Grizzle WE. Biomarker expression in prostatic intraepithelial neoplasia. Eur Urol 1996;30:153-66.
21. Rywlin AM. Intraepithelial melanocytes neoplasia (IMN) versus intraepithelial atypical melanocytic proliferation (IAMP). Am J Dermatopathol 1988;10:92.
22. Scholzen T, Gerdes J. The Ki-67 protein: from the know and the unknow. J Cell Physiol 2000;182:311-22.
23. Stapleton AM, Zbell P, Kattan MW, Yang G, Wheeler TM, Scardino PT, et al. Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer 1998;82:168-75.
24. Tavassoli FA, Norris HJ. A comparison of the results of long-term follow-up for atypical intraductal hyperplasia and intraductal hyperplasia of the breast. Cancer 1990;65:518.
25. The 1988 Bethesda System for reporting cervical/vaginal cytological diagnoses. National Cancer Institute Workshop. JAMA 1989;262:931-4.